The purpose of our review is to bring a better and updated understanding towards the activated pathological mechanisms in IBD patients during nutrition, novel pharmacotherapy (vedolizumab, ustekinumab, anti-IL23 p19 drugs), and vaccination. This evidence concerns the gene IL37 and inflammatory bowel disease.